Thanks BDAZ.

This really does highlight the need for Resverlogix to manage and control their messaging and the need to continuously reinforce the messages over time and in the broader media.

Perhaps with Mr Paradis now hired as VP of Investor relations and Sarah still in place they will have the extra resources for better message control and effective communications.

I distincly recall each of the points you made about RVX from reading the trial results and posts over the past few years. It is unfortunate for other researchers to have missed these important issues related to lack of persistent toxicity of rvx-208(apabetalone) tested through 6 months.

Regards

Toinv